HRP20251645T1 - Formulacije rifabutina i postupak priprave - Google Patents

Formulacije rifabutina i postupak priprave

Info

Publication number
HRP20251645T1
HRP20251645T1 HRP20251645TT HRP20251645T HRP20251645T1 HR P20251645 T1 HRP20251645 T1 HR P20251645T1 HR P20251645T T HRP20251645T T HR P20251645TT HR P20251645 T HRP20251645 T HR P20251645T HR P20251645 T1 HRP20251645 T1 HR P20251645T1
Authority
HR
Croatia
Prior art keywords
rifabutin
formulations
preparation procedure
procedure
preparation
Prior art date
Application number
HRP20251645TT
Other languages
English (en)
Croatian (hr)
Inventor
Sergio Lociuro
Stefano Biondi
Glenn E. Dale
Marilyne BOUROTTE
Marc Gitzinger
Original Assignee
BioVersys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioVersys AG filed Critical BioVersys AG
Publication of HRP20251645T1 publication Critical patent/HRP20251645T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20251645TT 2019-09-12 2020-08-03 Formulacije rifabutina i postupak priprave HRP20251645T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962899257P 2019-09-12 2019-09-12
US201962902019P 2019-09-18 2019-09-18
US201962941160P 2019-11-27 2019-11-27
EP20768379.8A EP4027976B1 (en) 2019-09-12 2020-08-03 Rifabutin compositions and method of making
PCT/IB2020/000648 WO2021048612A1 (en) 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions

Publications (1)

Publication Number Publication Date
HRP20251645T1 true HRP20251645T1 (hr) 2026-02-13

Family

ID=72428294

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20251645TT HRP20251645T1 (hr) 2019-09-12 2020-08-03 Formulacije rifabutina i postupak priprave

Country Status (23)

Country Link
US (1) US12370184B2 (cg-RX-API-DMAC7.html)
EP (2) EP4027976B1 (cg-RX-API-DMAC7.html)
JP (2) JP7777518B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220103697A (cg-RX-API-DMAC7.html)
CN (4) CN113015519B (cg-RX-API-DMAC7.html)
AU (2) AU2020346414B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022004659A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154318A1 (cg-RX-API-DMAC7.html)
DK (1) DK4027976T3 (cg-RX-API-DMAC7.html)
ES (1) ES3056897T3 (cg-RX-API-DMAC7.html)
FI (1) FI4027976T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251645T1 (cg-RX-API-DMAC7.html)
LT (1) LT4027976T (cg-RX-API-DMAC7.html)
MX (1) MX2022003075A (cg-RX-API-DMAC7.html)
MY (1) MY210244A (cg-RX-API-DMAC7.html)
PH (1) PH12022550606A1 (cg-RX-API-DMAC7.html)
PL (1) PL4027976T3 (cg-RX-API-DMAC7.html)
PT (1) PT4027976T (cg-RX-API-DMAC7.html)
RS (1) RS67627B1 (cg-RX-API-DMAC7.html)
SI (1) SI4027976T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500491T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021048612A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202203357B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364065A1 (en) * 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies
WO2026022215A1 (en) * 2024-07-23 2026-01-29 BioVersys AG Lyophilized formulations of rifabutin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6645508B1 (en) 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
CN1775214A (zh) * 2005-11-18 2006-05-24 武汉大学 利福喷丁、利福平、利福布丁或利福定注射剂及其制备方法
CA2641064C (en) * 2006-03-23 2017-03-07 Agriculture Victoria Services Pty Limited Antimicrobial protein
CN101362067A (zh) 2007-08-06 2009-02-11 天津科技大学 一种微胶囊制备方法
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
EA016410B1 (ru) * 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
WO2012106364A1 (en) 2011-01-31 2012-08-09 The Government Of The United States, As Represented By The Secretary Of The Army Methods and compositions for treating bacterial infections with iron chelators
CN102178604B (zh) * 2011-03-22 2014-03-05 中国人民解放军第三0九医院 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球
WO2015104668A2 (en) 2014-01-09 2015-07-16 Camus Pharma Pvt. Ltd. Lyophilized formulations for parenteral use
WO2016014437A1 (en) 2014-07-21 2016-01-28 Hiroaki Serizawa Ophthalmic compositions of rifamycins and uses thereof
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
WO2016178240A1 (en) * 2015-05-04 2016-11-10 Gufic Biosciences Limited A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof
CA3055311A1 (en) 2017-02-07 2018-08-16 Stc.Unm Isotope enhanced ambroxol for long lasting autophagy induction
US11701346B2 (en) 2018-11-28 2023-07-18 University Of Southern California Rifabutin for the treatment of acinetobacter baumannii

Also Published As

Publication number Publication date
AU2025283482A1 (en) 2026-01-15
RS67627B1 (sr) 2026-02-27
CN120267667A (zh) 2025-07-08
CA3154318A1 (en) 2021-03-18
WO2021048612A1 (en) 2021-03-18
MY210244A (en) 2025-09-04
CN113015519A (zh) 2021-06-22
PL4027976T3 (pl) 2026-02-16
US20240000759A1 (en) 2024-01-04
SMT202500491T1 (it) 2026-03-09
KR20220103697A (ko) 2022-07-22
FI4027976T3 (fi) 2025-12-12
DK4027976T3 (da) 2025-12-22
CN113015519B (zh) 2025-03-28
PT4027976T (pt) 2025-12-23
US12370184B2 (en) 2025-07-29
CN120267666A (zh) 2025-07-08
JP7777518B2 (ja) 2025-11-28
SI4027976T1 (sl) 2026-02-27
ES3056897T3 (en) 2026-02-25
PH12022550606A1 (en) 2023-01-23
EP4027976B1 (en) 2025-10-01
JP2022548858A (ja) 2022-11-22
JP2026027477A (ja) 2026-02-18
CN120267668A (zh) 2025-07-08
ZA202203357B (en) 2023-12-20
EP4748371A1 (en) 2026-05-27
LT4027976T (lt) 2026-01-12
EP4027976A1 (en) 2022-07-20
BR112022004659A2 (pt) 2022-06-21
MX2022003075A (es) 2022-07-11
AU2020346414B2 (en) 2025-10-02
AU2020346414A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
IL287069B2 (en) Fat compound and preparation thereof
IL285178A (en) Compounds and uses thereof
IL283134A (en) Alcohol-resistant drug formulations
IL288104A (en) Heterocyclic compounds, preparation methods and uses thereof
IL283549A (en) Carbonate aggregate compositions and methods of making and using the same
JP2018172409A5 (ja) 15−hepeを含む組成物および同組成物を使用する方法
IL264065A (en) Oral gastroretentive formulations and uses thes thereof
SG11202105730TA (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
PL3381451T3 (pl) Kompozycja farmaceutyczna stosowana do redukcji zlokalizowanej tkanki tłuszczowej i zastosowanie kompozycji farmaceutycznej
IL280937A (en) Vitamin d pediatric dosage forms, methods of making and using
DK3710036T3 (da) Stable ascorbic acid compositions and methods of using the same
EP4167937A4 (en) PROBIOTIC SKIN FORMULATIONS
DK4233850T3 (da) Kapselformuleringer
DK3981390T3 (da) Farmaceutisk lacosamid-sammensætning og farmaceutisk præparat deraf
IL284514A (en) Halo-allylamine compounds and use thereof
EP3897593A4 (en) CANNABINOID FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS
IL269884B1 (en) Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
EP3914234A4 (en) Pharmaceutical compositions
EP3773654C0 (en) POLYPHARMACEUTICAL DRUG COMPOSITIONS AND ASSOCIATED METHODS
IL282157A (en) Compounds and therapeutic uses thereof
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
IL276430A (en) A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use
EP4034113A4 (en) THERAPEUTIC FORMULATIONS AND THEIR USES
IL286713A (en) Liposomal formulations, and methods of using and preparing thereof
IL269305A (en) Cannabinoid formulations and dosage